AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract about the research platform NeuroRestore and its role in neuroprotection has been accepted for a presentation at ISMND 2022, which this year will be held in Athens, Greece, on October 10-12.
The abstract, titled The Trk-PAM ACD856 improves mitochondrial function and increase BDNF levels in primary cortical neurons, will be presented at the international conference organized by the International Society for Molecular Neurodegeneration (ISMND 2022) by Pontus Forsell, Head of Research and Discovery at AlzeCure. Other Co-authors include Cristina Parrado, Sanja Juric, Märta Dahlström and Johan Sandin, CSO at AlzeCure.
The presentation includes study results showing that the leading drug candidate in the NeuroRestore platform, ACD856, has a potential neuroprotective effect. New preclinical data show that the substance, in addition to strengthening the signaling, also increases the release of Brain Derived Neurotrophic Factor, BDNF, a so-called neurotrophin that has a very central role in memory formation, but also in maintaining normal nerve cell function and protecting them from damage. Moreover, ACD856 has a positive effect both on mitochondrial function and on cell survival, which could indicate potential disease-modifying effects of the substance.
"Our results show that ACD856 has both memory-enhancing effects and positive and protective effects on nerve cells, which is of significant importance in neurodegenerative diseases characterized by reduced cognitive function and impaired nerve cell function," says Pontus Forsell. "The fact that ACD856 also increases the levels of BDNF can be of great importance not only for neurodegenerative diseases, but also for disorders such as depression and traumatic brain injury".
"It is very exciting to see that ACD856, in addition to the memory enhancement we have previously observed, also has potential disease-modifying effects. The results further strengthen the commercial opportunity for our research platform NeuroRestore, which includes ACD856," says Martin Jönsson, CEO at AlzeCure Pharma AB.
The abstract and the poster will be available on AlzeCure's website after the presentation (https://www.alzecurepharma.se/en/presentations-and-interviews/).
